Ek Khoon Tan1, Andrew Bentall2,3, Patrick G Dean1,3, Mohammed F Shaheen1, Mark D Stegall1,3, Carrie A Schinstock2,3. 1. Division of Transplantation Surgery, Mayo Clinic, Rochester, MN. 2. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN. 3. Mayo Clinic William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.
Abstract
BACKGROUND: Active antibody-mediated rejection (AMR) that occurs during the amnestic response within the first month posttransplant is a rare but devastating cause of early allograft loss after kidney transplant. Prior reports of eculizumab treatment for AMR have been in heterogeneous patient groups needing salvage therapy or presenting at varied time points. We investigated the role of eculizumab as primary therapy for active AMR early posttransplant. METHODS: We performed a retrospective observational study of a consecutive cohort of solitary kidney transplant recipients who were transplanted between January 1, 2014, and January 31, 2018, and had AMR within the first 30 days posttransplant and treated with eculizumab ± plasmapheresis. RESULTS: Fifteen patients had early active AMR at a median (interquartile range [IQR]) of 10 (7-11) days posttransplant and were treated with eculizumab ± plasmapheresis. Thirteen cases were biopsy proven, and 2 cases were presumed on the basis of donor-specific antibody trends and allograft function. Within 1 week of treatment, the median estimated glomerular filtration rate increased from 21 to 34 mL/min (P = 0.001); and persistent active AMR was only found in 16.7% (2/12) of biopsied patients within 4-6 months. No graft losses occurred, and at last follow-up (median [IQR] of 13 [12-19] mo), the median IQR estimated glomerular filtration rate increased to 52 (46-60) mL/min. CONCLUSIONS: Prompt eculizumab treatment as primary therapy is safe and effective for early active AMR after kidney transplant or abrupt increases in donor-specific antibodies when biopsy cannot be performed for diagnosis confirmation.
BACKGROUND: Active antibody-mediated rejection (AMR) that occurs during the amnestic response within the first month posttransplant is a rare but devastating cause of early allograft loss after kidney transplant. Prior reports of eculizumab treatment for AMR have been in heterogeneous patient groups needing salvage therapy or presenting at varied time points. We investigated the role of eculizumab as primary therapy for active AMR early posttransplant. METHODS: We performed a retrospective observational study of a consecutive cohort of solitary kidney transplant recipients who were transplanted between January 1, 2014, and January 31, 2018, and had AMR within the first 30 days posttransplant and treated with eculizumab ± plasmapheresis. RESULTS: Fifteen patients had early active AMR at a median (interquartile range [IQR]) of 10 (7-11) days posttransplant and were treated with eculizumab ± plasmapheresis. Thirteen cases were biopsy proven, and 2 cases were presumed on the basis of donor-specific antibody trends and allograft function. Within 1 week of treatment, the median estimated glomerular filtration rate increased from 21 to 34 mL/min (P = 0.001); and persistent active AMR was only found in 16.7% (2/12) of biopsied patients within 4-6 months. No graft losses occurred, and at last follow-up (median [IQR] of 13 [12-19] mo), the median IQR estimated glomerular filtration rate increased to 52 (46-60) mL/min. CONCLUSIONS: Prompt eculizumab treatment as primary therapy is safe and effective for early active AMR after kidney transplant or abrupt increases in donor-specific antibodies when biopsy cannot be performed for diagnosis confirmation.
Authors: J E Locke; C M Magro; A L Singer; D L Segev; M Haas; A T Hillel; K E King; E Kraus; L M Lees; J K Melancon; Z A Stewart; D S Warren; A A Zachary; R A Montgomery Journal: Am J Transplant Date: 2008-10-31 Impact factor: 8.086
Authors: M Crespo; M Pascual; N Tolkoff-Rubin; S Mauiyyedi; A B Collins; D Fitzpatrick; M L Farrell; W W Williams; F L Delmonico; A B Cosimi; R B Colvin; S L Saidman Journal: Transplantation Date: 2001-03-15 Impact factor: 4.939
Authors: D Viglietti; C Gosset; A Loupy; L Deville; J Verine; A Zeevi; D Glotz; C Lefaucheur Journal: Am J Transplant Date: 2016-03-03 Impact factor: 8.086
Authors: James M Gloor; Steven R DeGoey; Alvaro A Pineda; S Breanndan Moore; Mikel Prieto; Scott L Nyberg; Timothy S Larson; Matthew D Griffin; Stephen C Textor; Jorge A Velosa; Thomas R Schwab; Lynette A Fix; Mark D Stegall Journal: Am J Transplant Date: 2003-08 Impact factor: 8.086
Authors: C Lefaucheur; D Nochy; J Andrade; J Verine; C Gautreau; D Charron; G S Hill; D Glotz; C Suberbielle-Boissel Journal: Am J Transplant Date: 2009-05 Impact factor: 8.086
Authors: J M Burns; L D Cornell; D K Perry; H S Pollinger; J M Gloor; W K Kremers; M J Gandhi; P G Dean; M D Stegall Journal: Am J Transplant Date: 2008-10-24 Impact factor: 8.086
Authors: M Haas; A Loupy; C Lefaucheur; C Roufosse; D Glotz; D Seron; B J Nankivell; P F Halloran; R B Colvin; Enver Akalin; N Alachkar; S Bagnasco; Y Bouatou; J U Becker; L D Cornell; J P Duong van Huyen; I W Gibson; Edward S Kraus; R B Mannon; M Naesens; V Nickeleit; P Nickerson; D L Segev; H K Singh; M Stegall; P Randhawa; L Racusen; K Solez; M Mengel Journal: Am J Transplant Date: 2018-01-21 Impact factor: 8.086
Authors: Bartlomiej J Witczak; Søren E Pischke; Anna V Reisæter; Karsten Midtvedt; Judith K Ludviksen; Kristian Heldal; Trond Jenssen; Anders Hartmann; Anders Åsberg; Tom E Mollnes Journal: Front Immunol Date: 2021-10-25 Impact factor: 7.561
Authors: Carrie A Schinstock; Roslyn B Mannon; Klemens Budde; Anita S Chong; Mark Haas; Stuart Knechtle; Carmen Lefaucheur; Robert A Montgomery; Peter Nickerson; Stefan G Tullius; Curie Ahn; Medhat Askar; Marta Crespo; Steven J Chadban; Sandy Feng; Stanley C Jordan; Kwan Man; Michael Mengel; Randall E Morris; Inish O'Doherty; Binnaz H Ozdemir; Daniel Seron; Anat R Tambur; Kazunari Tanabe; Jean-Luc Taupin; Philip J O'Connell Journal: Transplantation Date: 2020-05 Impact factor: 5.385